Serum Institute OF India Private Limited

Serum Institute of India Private Limited (SII), established in 1966 by Cyrus S. Poonawalla, is a leading Indian biotechnology and biopharmaceutical company headquartered in Pune, Maharashtra. The company specializes in the production of vaccines, biopharmaceuticals, and generic drugs, serving a global market. As of the latest available data, SII operates as a private limited company with a Corporate Identification Number (CIN) of U80903PN1984PTC032945. The company's authorized share capital is ₹550,000,000, with a paid-up capital of ₹48,192,530. SII employs a substantial workforce, contributing significantly to the Indian pharmaceutical sector. The official website of Serum Institute of India is www.seruminstitute.com.

Serum Institute of India operates multiple manufacturing facilities in Pune, Maharashtra, India. These state-of-the-art plants are equipped with advanced technologies to produce a wide range of vaccines and biopharmaceuticals. The facilities adhere to stringent quality control measures and comply with international standards, ensuring the production of high-quality products. Specific details regarding the capacities and specializations of each plant are proprietary and not publicly disclosed.

The leadership of Serum Institute of India is helmed by Cyrus S. Poonawalla, who serves as the Chairman and Managing Director. His son, Adar C. Poonawalla, holds the position of Chief Executive Officer (CEO). Under their guidance, the company has expanded its global footprint and diversified its product portfolio, solidifying its position as a leader in the vaccine manufacturing industry. (craft.co)

Serum Institute of India has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has achieved World Health Organization (WHO) prequalification for several of its products, such as the 10-valent pneumococcal conjugate vaccine, Pneumosil, which received prequalification in January 2020. This prequalification facilitates access to international markets and underscores the company's commitment to meeting global health standards. Additionally, SII's products are registered and approved in various countries, enabling the company to supply vaccines to a broad spectrum of markets.

Serum Institute of India has made significant inroads into emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's WHO prequalification status for products like Pneumosil has been instrumental in facilitating access to these regions. By offering affordable and high-quality vaccines, SII addresses the pressing health needs of these areas, contributing to the global effort in disease prevention and control.

Serum Institute of India's geographic strategy demonstrates a balanced approach between diversification and concentration. While the company has a strong foothold in emerging markets, it also maintains a significant presence in developed markets through WHO prequalification and regulatory approvals. This strategic positioning mitigates concentration risk and aligns with the company's mission to provide affordable vaccines globally. The strategic direction focuses on expanding market access, enhancing production capabilities, and fostering partnerships to address global health challenges.

Serum Institute of India has registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), indicating compliance with U.S. regulatory standards. The facility has undergone multiple FDA inspections, with some resulting in observations. However, specific details regarding the nature of these observations and subsequent corrective actions are not publicly disclosed. The company's commitment to adhering to FDA regulations underscores its dedication to maintaining high-quality manufacturing practices.

Serum Institute of India has achieved World Health Organization (WHO) prequalification for several of its products, including Pneumosil, a 10-valent pneumococcal conjugate vaccine. This prequalification, granted in January 2020, signifies that the product meets international standards for quality, safety, and efficacy. Additionally, SII's manufacturing facilities comply with European Union Good Manufacturing Practice (EU GMP) standards, ensuring that products meet the stringent requirements of the European market.

In India, Serum Institute of India holds manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority. The company also obtains approvals from state drug controllers for the sale and distribution of its products within India. For export purposes, SII secures No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating the international distribution of its products. These regulatory compliances reflect the company's adherence to national standards and its commitment to quality assurance.

Specific details regarding recent regulatory actions, such as FDA Form 483 observations, warning letters, or import alerts, are not publicly disclosed for Serum Institute of India. The company maintains a focus on compliance with international and national regulatory standards, ensuring the safety and efficacy of its products.

Serum Institute of India operates in a competitive landscape with several key players in the vaccine manufacturing industry. Top competitors include multinational corporations such as Pfizer, Merck, and GlaxoSmithKline, as well as other Indian manufacturers like Bharat Biotech and Biological E. SII distinguishes itself through its extensive product portfolio, including vaccines for diseases like polio, hepatitis B, and COVID-19, and its commitment to affordability and accessibility. The company's focus on large-scale production and global distribution further strengthens its competitive position. (give.do)

Serum Institute of India's key differentiators include its status as the world's largest vaccine manufacturer by volume, producing over 1.5 billion doses annually. (give.do) The company's commitment to affordability ensures that life-saving vaccines are accessible to underprivileged populations globally. Additionally, SII's extensive experience in vaccine development and manufacturing, coupled with its robust regulatory compliance, positions it as a leader in the biopharmaceutical industry.

Serum Institute of India's current strategic direction focuses on expanding its global footprint by entering new markets and enhancing its product portfolio. The company is investing in research and development to innovate and improve existing vaccines and to develop new ones, including those for emerging infectious diseases. Future outlooks indicate a continued emphasis on large-scale production capabilities, strategic partnerships, and maintaining high standards of quality and safety to address global health challenges effectively.

Serum Institute of India has a strong track record in the pharmaceutical industry, with a substantial export volume and consistency in product quality. The company's adherence to international regulatory standards and its commitment to affordability and accessibility make it a reliable supplier for global markets. Indicators of reliability include its WHO prequalification status and compliance with EU GMP standards, reflecting the company's dedication to maintaining high-quality manufacturing practices.

Importers should verify the following certifications when considering Serum Institute of India as a supplier:

• FDA Facility Registration: Confirm the registration of SII's manufacturing facility with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S. regulatory standards.

• WHO Prequalification: Verify the prequalification status of SII's products with the World Health Organization (WHO) to ensure they meet international standards for quality, safety, and efficacy.

• EU GMP Certification: Ensure that SII's manufacturing facilities comply with European Union Good Manufacturing Practice (EU GMP) standards, indicating adherence to stringent quality control measures.

• CDSCO Manufacturing License: Confirm that SII holds valid manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO) in India, ensuring compliance with national regulatory requirements.

To verify each certification, importers can consult the respective regulatory bodies' official websites or contact SII directly for documentation.

When conducting due diligence on Serum Institute of India, consider the following steps:

• Regulatory Compliance Verification: Confirm that SII holds the necessary certifications and licenses from relevant regulatory bodies, including the FDA, WHO, EU GMP, and CDSCO.

• Quality Assurance Assessment: Review SII's quality control measures and manufacturing practices to ensure they meet international standards.

• Financial Stability Evaluation: Assess SII's financial health by reviewing financial statements and credit reports to ensure the company's stability and ability to fulfill contractual obligations.

• Supply Chain Reliability Check: Evaluate SII's supply chain processes to ensure timely and consistent delivery of products.

• Re